Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

<p>CONSORT Diagram</p>

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Aurelius Omlin (14971513) (author)
Бусад зохиолчид:	Richard Cathomas (14971516) (author), Gunhild von Amsberg (14971519) (author), Christoph Reuter (14971522) (author), Susan Feyerabend (14971525) (author), Wolfgang Loidl (14971528) (author), Martin Boegemann (14971531) (author), Anja Lorch (14971534) (author), Axel Heidenreich (14971537) (author), Igor Tsaur (14971540) (author), Julian Larcher-Senn (14971543) (author), Stefan A.J. Buck (14971546) (author), Ron H.J. Mathijssen (14971549) (author), Ulrich Jaehde (14971552) (author), Silke Gillessen (14971555) (author), Markus Joerger (14971558) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Therapeutic Research and Development Clinical Research and Trials Methods and Technology Chemotherapy Clinical-Stage Research Computational Methods Algorithms Genitourinary Cancers Prostate cancer Pharmacology Pharmacokinetics and pharmacodynamics
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
-н: Aurelius Omlin (14971513)
Хэвлэсэн: (2025)

Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
-н: Evan C. Chen (15054014)
Хэвлэсэн: (2025)

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
-н: Evan C. Chen (15054014)
Хэвлэсэн: (2025)

Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
-н: Evan C. Chen (15054014)
Хэвлэсэн: (2025)

Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
-н: Evan C. Chen (15054014)
Хэвлэсэн: (2025)

Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
-н: Evan C. Chen (15054014)
Хэвлэсэн: (2025)

Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
-н: Evan C. Chen (15054014)
Хэвлэсэн: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
-н: Dwight H. Owen (15034782)
Хэвлэсэн: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
-н: Dwight H. Owen (15034782)
Хэвлэсэн: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
-н: Dwight H. Owen (15034782)
Хэвлэсэн: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
-н: Dwight H. Owen (15034782)
Хэвлэсэн: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
-н: Dwight H. Owen (15034782)
Хэвлэсэн: (2025)

Data Sheet 1_Population pharmacokinetics/pharmacodynamics and safety of YPEG-rhGH in elderly subjects.docx
-н: Yajie He (20323682)
Хэвлэсэн: (2025)

Supplementary Figure S1 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
-н: Yan Zhou (15053225)
Хэвлэсэн: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
-н: Chong Kin Liam (15331321)
Хэвлэсэн: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
-н: Chong Kin Liam (15331321)
Хэвлэсэн: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
-н: Chong Kin Liam (15331321)
Хэвлэсэн: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
-н: Chong Kin Liam (15331321)
Хэвлэсэн: (2025)

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
-н: Zev A. Wainberg (15047031)
Хэвлэсэн: (2025)

Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
-н: Elizabeth R. Tucker (15053624)
Хэвлэсэн: (2025)

Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
-н: Elizabeth R. Tucker (15053624)
Хэвлэсэн: (2025)

Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
-н: Elizabeth R. Tucker (15053624)
Хэвлэсэн: (2025)

Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
-н: Elizabeth R. Tucker (15053624)
Хэвлэсэн: (2025)

Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
-н: Elizabeth R. Tucker (15053624)
Хэвлэсэн: (2025)

Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
-н: Elizabeth R. Tucker (15053624)
Хэвлэсэн: (2025)

Supplementary Figure 1 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
-н: Michelle L. Mierzwa (14963463)
Хэвлэсэн: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
-н: Arun Kanakkanthara (14937731)
Хэвлэсэн: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
-н: Arun Kanakkanthara (14937731)
Хэвлэсэн: (2025)

Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
-н: Alyssa C. Flint (16676029)
Хэвлэсэн: (2025)

Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
-н: Alyssa C. Flint (16676029)
Хэвлэсэн: (2025)

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
-н: Sanna Pikkusaari (15055802)
Хэвлэсэн: (2025)

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
-н: Sanna Pikkusaari (15055802)
Хэвлэсэн: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
-н: Ulka N. Vaishampayan (15051039)
Хэвлэсэн: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
-н: Ulka N. Vaishampayan (15051039)
Хэвлэсэн: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
-н: Ulka N. Vaishampayan (15051039)
Хэвлэсэн: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
-н: Ulka N. Vaishampayan (15051039)
Хэвлэсэн: (2025)

Supplementary Data 1 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
-н: Gregory L. Beatty (15087193)
Хэвлэсэн: (2025)

Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
-н: Gregory L. Beatty (15087193)
Хэвлэсэн: (2025)

Supplementary Figure S1 from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
-н: Zachary Quinn (15052893)
Хэвлэсэн: (2025)

Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
-н: Fabrice Barlesi (15045504)
Хэвлэсэн: (2025)

Cannot write session to /tmp/vufind_sessions/sess_edpnv67nl027abs9arqvftkpev